ClinicalTrials.gg
Sign In
Drug

Pemetrexed clinical trials

Also written Alimta, LY231514, Pemfexy and NSC-698037.

studies test it
433
open now
45
in phase 3
67
first study started
1998

How each study uses Pemetrexed is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Pemetrexed studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Approvals

The first approval found in each region, with its record

United States
19 Aug 2004 · ALIMTA · NDA 021677 (FDA, Drugs@FDA)
European Union
20 Sept 2004 · Alimta · EMEA/H/C/000564 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Pemetrexed
286
pemetrexed disodium
52
MTA
16
Multitargeted Antifolate
10
N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt
9

Brand

Alimta
166
Pemfexy
6

Development codes

LY231514
78
NSC-698037
5

In one entry with another drug

Given together, or one or the other

Pemetrexed/Cisplatin
5
Pemetrexed/Carboplatin
4
Pemetrexed, cisplatin
2
Tislelizumab, Carboplatin, Pemetrexed
2
pemetrexed plus carboplatin
2

Studies by the year they started

419 studies that test it; most in 2006 (50)

Studies that test Pemetrexed, by start year
YearStudies
19981
19991
20012
20023
200312
200417
200546
200650
200726
200824
200925
201014
20118
201211
201313
20147
201516
201612
201720
201814
201915
202018
20219
202216
20238
202418
20257
20266

By phase

A phase 1/2 study counts in both.

Early Phase 1
4
Phase 1
80
Phase 2
303
Phase 3
67
Phase 4
11
No phase
8

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Carcinoma, Non-Small-Cell Lung
197
Lung Neoplasms
21
Mesothelioma, Malignant
15
Breast Neoplasms
12
Head and Neck Neoplasms
10
Colorectal Neoplasms
9
Neoplasms
8
Mesothelioma
7
Ovarian Neoplasms
7
Adenocarcinoma of Lung
6
Small Cell Lung Carcinoma
6
Squamous Cell Carcinoma of Head and Neck
5

Who runs them

Industry 141 · Other 292

Eli Lilly and Company (94) · Alliance for Clinical Trials in Oncology (10) · AstraZeneca (9) · National Cancer Institute (NCI) (7) · M.D. Anderson Cancer Center (7) · Sun Yat-sen University (7) · Memorial Sloan Kettering Cancer Center (7) · Hoffmann-La Roche (6)

Often tested with

Tested in the same studies.

Cisplatin (113) · Carboplatin (112) · Gemcitabine (57) · Bevacizumab (45) · Paclitaxel (39) · Docetaxel (28) · Pembrolizumab (15) · Erlotinib (15)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 47 phase 3 studies under way

Pemetrexed is the comparator. A study of two new drugs counts under both.

  • 5Sacituzumab tirumotecan · Merck Sharp & Dohme LLC, Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. · next primary completion Dec 2026
  • 4Izalontamab brengitecan · Bristol-Myers Squibb, Sichuan Baili Pharmaceutical Co., Ltd. · next primary completion Dec 2028
  • 3Datopotamab deruxtecan · AstraZeneca, Daiichi Sankyo · next primary completion Nov 2027
  • 3Durvalumab · AstraZeneca
  • 2Trastuzumab deruxtecan · AstraZeneca, Daiichi Sankyo · next primary completion Apr 2030
  • 2Tremelimumab · AstraZeneca
  • 2ASKC202 · Jiangsu Aosaikang Pharmaceutical Co., Ltd. · next primary completion Oct 2027
  • 2Adebrelimab · Suzhou Suncadia Biopharmaceuticals Co., Ltd., Shanghai Shengdi Pharmaceutical Co., Ltd · next primary completion Oct 2028
Reaching primary completion within a year · 14, 5 in phase 3

Studies that test Pemetrexed, phase 3 first.

Studies

Open first, then newest update. How each study uses Pemetrexed is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 433

See all 433 studies that test Pemetrexed →

Given beside what is tested · 494 — Pemetrexed is usual care or a partner of the new treatment

Showing 20 of 494.

As the comparator · 109 — what is tested is compared with Pemetrexed

Showing 20 of 109.

Codes

What other systems call Pemetrexed · ClinicalTrials.gg INT006512

  • MeSH (NLM) D000068437PemetrexedConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 04Q9AIZ7NOPEMETREXEDConfirmed FDA, NLM, Wikidata
  • RxNorm 68446Confirmed FDA, Wikidata
  • Wikidata Q415220pemetrexedConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C61614PemetrexedOne source FDA
  • DrugBank DB00642One source Wikidata

Also registered as pemetrexed disodium (UNII 2PKU919BA9 · RxNorm 282443).

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.